Insulin-fc fusions and methods of use
AssigneeAkston Biosciences Corporation
InventorsThomas M. Lancaster, Todd C. Zion, Thillainayagam Sathiyaseelan, Sylaja Murikipudi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.
Claims20
An insulin-Fc fusion protein comprising an insulin polypeptide fused to a Fc domain, wherein the insulin polypeptide comprises a B-chain peptide, a C-chain peptide, and an A-chain peptide, wherein the amino acid sequence of the C-chain peptide is AAK (SEQ ID NO:
- 16), and optionally wherein the insulin-Fc fusion protein binds human insulin receptor at an IC50>5,000 nM in a competitive binding assay.
An insulin-Fc fusion protein comprising an insulin polypeptide fused to a Fc domain, wherein the insulin polypeptide comprises a B-chain peptide, a C-chain peptide, and an A-chain peptide,
- wherein the B-chain peptide comprises the amino acid sequence FVNQHLCGSHLVX1ALX2LVCGEX3GFFYTPK (SEQ ID NO:
- 28), wherein X1 is E or Q, X2 is Y or A, and X3 is R or E;
- and
- wherein the amino acid sequence of the C-chain peptide is AAK (SEQ ID NO:
- 16).
A recombinant nucleic acid sequence encoding an insulin-Fc fusion protein selected from the group consisting of SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, and SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.